OssDsign AB (publ) publishes year-end report 2019

OssDsign CEO Anders Lundqvist: “OssDsign AB finished an exciting and eventful year on a very strong note. Our strategy for, and investments in the US market, as presented in the IPO process generated the expected good results.”

The fourth quarter in figures

• Net sales amounted to TSEK 5 069 (4 220). 
• Loss after taxes amounted to TSEK 28 641 (15 755).
• Loss per share was SEK 1,6 (2,8).
• Cash flow from current operations was TSEK -24 023 (-26 887).
   

The full year in figures

• Net sales amounted to TSEK 16 873 (13 264).
• Loss after taxes amounted to TSEK 84 245 (56 011).
• Loss per share was SEK 5,5 (11,0). 
• Cash flow from current operations was TSEK -71 616 (-66 018).
   

Important events during the fourth quarter

• UK National Health Service contract award received. 
• First clinical experience with OssDsign implants on Japanese patients presented at the 78th Annual Meeting of the Japan Neurosurgical Society held in Osaka. 
• The European Patent Office (EPO) granted OssDsign an additional European Patent related to the company’s ceramic material technology.
• FDA clearance for OssDsign Cranial PSI Accessories received.
• Updated Post Market Surveillance data on the outcome of 670 cranioplasties using OssDsign Cranial PSI are in line with OssDsign’s previously published rate of complications - substantially lower than published data for traditional implants.
• Transition from master distributor to OssDsign USA Inc completed
   

Important events after the end of the fourth quarter

• No important events have occurred after the end of the period 
   

Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08, email: al@ossdsign.com 

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on February 13th, 2019

Tags: